The estimated Net Worth of Partners, L.P.Bradsher Neal... is at least 66.9 百万$ dollars as of 7 November 2023. Partners Neal owns over 289,140 units of Oncocyte stock worth over 31,210,853$ and over the last 11 years Partners sold OCX stock worth over 35,650,815$.
Sign up
Partners Neal OCX stock SEC Form 4 insiders trading
Partners has made over 15 trades of the Oncocyte stock since 2014, according to the Form 4 filled with the SEC. Most recently Partners bought 289,140 units of OCX stock worth 9,663,059$ on 7 November 2023.
The largest trade Partners's ever made was buying 6,003,752 units of Oncocyte stock on 13 April 2022 worth over 7,984,990$. On average, Partners trades about 423,408 units every 173 days since 2013. As of 7 November 2023 Partners still owns at least 10,068,017 units of Oncocyte stock.
You can see the complete history of Partners Neal stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Oncocyte
Over the last 9 years, insiders at Oncocyte have traded over 16,389,842$ worth of Oncocyte stock and bought 56,056,405 units worth 102,313,246$ . The most active insiders traders include Partners, L.P.Broadwood Cap...、Cell Therapeutics, Inc. Lin...、Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of 3,382,106$. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth 10,001$.
What does Oncocyte do?
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
What does Oncocyte's logo look like?
Complete history of Partners Neal stock trades at Staar Surgical Co、Oncocyte
Oncocyte executives and stock owners
Oncocyte executives and other stock owners filed with the SEC include:
-
Ronald Andrews,
President, Chief Executive Officer, Director -
Lyndal Hesterberg,
Chief Scientific Officer -
Mitchell Levine,
Chief Financial Officer -
Ronald A. Andrews Jr.,
CEO, Pres & Director -
Cavan Redmond,
Independent Chairman of the Board -
Andrew Last,
Independent Director -
Andrew Arno,
Independent Director -
Melinda Griffith,
Independent Director -
Bob Yedid,
Investor Relations -
Douglas Ross,
Chief Medical Officer -
Padma Sundar,
Senior Vice President - Marketing and Market Access -
Tony Kalajian,
Senior Vice President, Chief Accounting Officer -
Albert Parker,
Chief Operating Officer -
Dr. Michael D. West Ph.D.,
Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. -
Dr. Ekkehard Schutz M.D., Ph.D.,
Chief Technology Officer -
Robert S. Seitz,
Head of Immune Oncology -
Li Yu,
VP, Controller & Principal Accounting Officer -
Gisela A. Paulsen,
Chief Operating Officer -
Sara Riordan,
Director of Medical Education -
Dr. Michael D. West,
Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. -
Dr. Douglas T. Ross M.D., Ph.D.,
Chief Science Officer -
William Annett,
Advisor -
Gisela Paulsen,
Former President and COO -
Vida Investments, Llc Kamen...,
-
Karen B. Chapman,
Vice President of Research -
Alfred D Kingsley,
Director -
Don M Bailey,
Director -
William Annett,
President and CEO -
Michael D West,
Director -
Kristine C. Mechem,
VP of Marketing -
Partners, L.P.Broadwood Cap...,
-
Anish M. John,
Chief Financial Officer -
Aditya P. Mohanty,
Director -
Cell Therapeutics, Inc. Lin...,
-
James Yang Liu,
Sr Dir., Cntlr, PAO, Int PFO -
Jennifer L. Carter,
Director -
Li Yu,
VP Cntrllr/Prncpl Acctng Offcr -
Partners, L.P.Bradsher Neal...,
-
Lou Silverman,
Director -
Josh Riggs,
CEO and President -
John Peter Gutfreund,
-
Andrea S. James,
Chief Financial Officer